Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). van de Donk, N. J., Moreau, P., Garfall, A. L., Bhutani, M., Oriol, A., Nooka, A. K., Martin, T. G., Rosinol, L., Mateos, M., Bahlis, N. J., Popat, R., Besemer, B., Martinez-Lopez, J., Krishnan, A. Y., Delforge, M., Trancucci, D., Verona, R., Stephenson, T., Chastain, K., Sidana, S. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001053772003529